Ticagrelor monotherapy after 1 month of dual antiplatelet therapy (DAPT) was noninferior to standard 1-year DAPT among patients who had undergone percutaneous coronary intervention (PCI) with drug-eluting stents, according to results of the GLASSY* trial presented at ACC.19.
Dapagliflozin reduced the rate of MACE* by 16 percent in patients with type 2 diabetes (T2D) who had a prior myocardial infarction (MI) in one of DECLARE-TIMI 58 sub-analyses, boosting the drug’s chances of a label update for cardiovascular (CV) indication in addition to glucose lowering.
Undergoing primary percutaneous coronary intervention (PCI) through the transradial route did not confer survival benefit at 30 days in patients with acute myocardial infarction compared with the transfemoral approach, contrary to common belief.
Patients with acute, low-risk pulmonary embolism (PE) can be safely discharged within 2 days of hospitalization and treated with rivaroxaban out-of-hospital with a low incidence of recurrence, findings of the HoT-PE* study showed.
Switching from dual antiplatelet therapy (DAPT) to clopidogrel monotherapy just one month after stent implantation led to a reduction in bleeding without an increase in ischaemic events, the STOPDAPT-2* trial showed.
Two landmark studies on transcatheter aortic valve replacement (TAVR) showed that not only was TAVR noninferior to surgical AVR (SAVR) in patients with severe aortic stenosis (AS) at low surgical risk, it was superior over the latter in the PARTNER 3 trial using the SAPIEN 3 valve.
A telephone-delivered, nurse-provided, ‘blended’ collaborative care (CC) programme was better than usual care (UC) in improving health-related quality of life (HRQoL) and mood symptoms in patients with heart failure (HF) and comorbid depression, according to the results of the HOPEFUL HEART* trial presented at ACC.19.
The superiority of HeartMate 3 centrifugal-flow left ventricular assist device (LVAD) over the previous-generation HeartMate II device held up to the final analysis of the MOMENTUM 3* trial, accentuated by improved survival free of disabling events in patients with advanced heart failure (HF).
Use of the NOAC* apixaban led to less bleeding and hospitalizations compared with vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) who had a recent acute coronary syndrome (ACS) or had undergone percutaneous coronary intervention (PCI) and were on treatment with a P2Y12 inhibitor, reveals the AUGUSTUS study. Furthermore, dropping aspirin from the regimen shields these patients against bleeding risk without significant increase in ischaemic events.
The benefits of dapagliflozin in reducing the risk of cardiovascular (CV) death, hospitalization for heart failure (HHF), and renal outcomes* were consistent in patients with type 2 diabetes (T2D) regardless of whether or not they had peripheral artery disease (PAD), according to a subgroup analysis of the DECLARE-TIMI 58** trial. Moreover, dapagliflozin-treated patients did not have an elevated risk of limb ischaemic events.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.